Drugs / Peginterferon (PegIFNα-2a)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00561353 Background | Jan → Dec 2008 | chronic hepatitis C virus infection | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon (PegIFNα-2a) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00561353 ↗ |
| Known as | PegIFNα-2a | “Drug: Peginterferon (PegIFNα-2a)” NCT00561353 ↗ |
| Route | Subcutaneous | “One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22” NCT00561353 ↗ |